A Phase 2 interventional study of ECC4703 and Placebo in Adult Obesity and Weight Management, sponsored by Eccogene. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Eccogene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 151 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECC4703 orally QD + semaglutide SC once weekly
Drug: ECC4703 · Drug: Semaglutide
Placebo orally QD + semaglutide SC once weekly
Drug: Placebo · Drug: Semaglutide
orally QD
orally QD
SC once weekly
Percentage Change in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis
Time frame: Baseline (Week 9) to Week 20
Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Lean Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Total Body Fat Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Visceral Fat Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Glycemic Parameters from Baseline (Week 9) to Week 20
Change in HbA1c and fasting plasma glucose levels from baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Lipid Parameters from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Body Weight (kg) from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants Achieving ≥2% and ≥3% Reduction in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Alanine Aminotransferase (ALT) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Aspartate Aminotransferase (AST) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Alkaline Phosphatase (ALP) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Gamma-Glutamyl Transferase (GGT) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Frequency of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose through Week 20 (or end of study visit)
Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose through Week 20 (or end of study visit)
Laboratory Safety Evaluations
changes in clinical laboratory parameters, including hematology, serum chemistry, and urinalysis.
Time frame: Baseline through Week 20
Changes in 12-Lead Electrocardiogram (ECG) Parameters
Change in QT Interval, etc
Time frame: Baseline through Week 20
Changes in Vital Signs Findings
including blood pressure, etc
Time frame: Baseline through Week 20
Changes in Physical Examination Findings
including blood pressure, etc
Time frame: Baseline through Week 20
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 6 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ECC4703
Eccogene